Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial.
Journal of Affective Disorders August 15, 2025 Xinya Hong, Sen Xu, Gaozhong Sun et al. 3 citations
This multicenter, randomized, placebo-controlled, clinical trial was designed to investigate the efficacy and safety of esketamine (ESK) for smoking cessation. The study enrolled a sample of 236 patients diagnosed with lung cancer and major depression disorder (MDD). Treatment included intranasal delivery of ESK or placebo once a week for 8 sessions. The primary outcomes were self-reported and...
DOI: 10.1016/j.jad.2025.04.077 (opens in new tab)
Full text (opens in new tab)
Esketamine
Antidepressant
Major depression disorder
Smoking cessation
+10